Diligence memo · auto-generated · as of July 2, 2026

Amarin Corp Plc\Uk

Amarin Corp Plc\Uk has raised $70M over 1 round; too few niche peers to rank its valuation yet.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Amarin Corp Plc\Uk operates in Pharmaceuticals, based in DUBLIN.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Amarin Corp Plc\Uk has raised $70M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).

Largest single filing: $70M on 2009-10-16.

Most recent recorded round closed around 2009-10-16.

Valuation (modeled)modeled

Provath models Amarin Corp Plc\Uk at approximately $2.5B (range $227M–$6.5B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Too few comparable companies in this niche to rank the valuation fairly yet.

Financing rhythm & timingmixed

Last raise 16.7 yr ago; this sector typically re-raises about every 13 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 86% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 96% of those peers.

Closest niche peers: Xanodyne Pharmaceuticals Inc, Ikaria Holdings Inc.

Peoplefiled

7 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.